Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Inrebic is a prescription kinase inhibitor containing fedratinib. It is indicated for adults with intermediate-2 or high-risk primary myelofibrosis or secondary myelofibrosis that developed after polycythemia vera or essential thrombocythemia. Each capsule contains 100 mg of fedratinib.
read more about inrebic ...Fedratinib inhibits Janus-associated kinase 2 and mutant JAK2 activity and also has activity against FLT3. JAK2 signaling is involved in blood-cell production and is abnormally active in myelofibrosis. Inhibition reduces abnormal signaling linked to the disease.
Inrebic is used in adults with intermediate-2 or high-risk primary or secondary myelofibrosis. The recommended regimen requires a baseline platelet count of at least 50 ? 10^9 per L. Thiamine levels and blood counts are checked before treatment.
The recommended dose is 400 mg by mouth once daily with or without food when baseline platelets are at least 50 ? 10^9 per L. All patients receive thiamine 100 mg by mouth daily during treatment. Dose reduction is used with strong CYP3A4 inhibitors or severe kidney impairment.
Inrebic carries a boxed warning for serious and fatal encephalopathy, including Wernicke encephalopathy. Treatment does not start in patients with thiamine deficiency. Other serious concerns include anemia, thrombocytopenia, severe gastrointestinal toxicity, liver toxicity, elevated amylase or lipase, uveitis, major cardiovascular events, thrombosis, and secondary malignancies.
Inrebic treats intermediate-2 or high-risk primary or secondary myelofibrosis in adults.
The recommended dose is 400 mg once daily when baseline platelets are at least 50 ? 10^9 per L.
Low thiamine increases the risk of Wernicke encephalopathy, so deficiency is corrected before treatment begins.
Yes. The boxed warning concerns serious and fatal encephalopathy, including Wernicke encephalopathy.
Fedratinib Hydrochloride. https://www.cancer.gov/about-cancer/treatment/drugs/fedratinibhydrochloride. Date Accessed October 5, 2026.
Fedratinib: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a619058.html. Date Accessed October 5, 2026.
INREBIC (Fedratinib) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7. Date Accessed October 5, 2026.
INREBIC Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212327s007lbl.pdf. Date Accessed October 5, 2026.
Updated Results of the Placebo-Controlled, Phase III JAKARTA Trial of Fedratinib in Patients With Intermediate-2 or High-Risk Myelofibrosis. https://pubmed.ncbi.nlm.nih.gov/34331348/. Date Accessed October 5, 2026.